Roche: Strong phase III data for ocrelizumab in PPMS and RRMS

BUY – Top Pick, Fair Value CHF327 (+29%)
News published on October Friday 9, 2015
Share on

Ocrelizumab phase III data with be presented today and tomorrow at ECTRIMS. The tougher the endpoints in RRMS, the better the results i.e. mixed on ARR but very good on disability and MRI measures. They are also very solid in PPMS and make ocrelizumab a potential new SoC. Based on these results, we confirm our 2021 sales target of USD3bn (80% PoS), where CS is 3x lower.


For more information, please contact marketing@bryangarnier.com 

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities